INHIBIKASE THERAPEUTICS INC reports a Return on Equity (ROE) of -30.40%.

What is IKT's dividend yield?

INHIBIKASE THERAPEUTICS INC offers a dividend yield of 0.00%.

What is IKT's Deepscope Quality Score?

Deepscope rates IKT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy IKT?

Deepscope's AI Timing Score for IKT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does IKT belong to?

INHIBIKASE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Cổ phiếu IKT (NASDAQ) | INHIBIKASE THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-09 | FS: 2026-03-31)

IKT

INHIBIKASE THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 94

USD 1.67

0.05 (3.09%) Day Change

Watchlist Portfolio Compare Chart

0.03

D/E

-30.4%

ROE

-29.4%

ROA

0.00%

Div Yield

INHIBIKASE THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.67 Price 0.05 (3.09%) Day Change	NEWS SCORE: 94

IKT Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...

Yếu tố Chất lượng

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.67
PBV / Sector	1.28 / 4.71 GOOD
Earning Per Share	-0.40

PE / Sector	N/A / 17.58
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	1.17 M GREAT
Average 1W Daily Value	1.09 M GREAT

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 468.85
NPM Average (%) / Sector	-10,965.30 / -1,531.69
NPM Change Average (%) / Sector	N/A / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-29.40 / 31.69
ROA Average (%) / Sector	-57.50 / -353.18
ROA Change Average (%) / Sector	2.07 / 5,214.65
ROE (%) / Sector	-30.40 / 10.58
ROE Average (%) / Sector	-69.30 / 27.64
ROE Change Average (%) / Sector	5.96 / 2,048.88
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.68

Chi tiết đăng ký

Analyze Date	2026-06-10 09:43:58
Symbol	IKT
Name	INHIBIKASE THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	132.03 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	215.21 / 8,889.42

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1000 N. West Street, Wilmington, DE, United States, 19801

Phone: 302 295 3800

Website: https://www.inhibikase.com

Sector: Healthcare >> Biotechnology

Description: Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.